FibroGen, Inc.
FGEN
$5.75
$0.5911.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 102.85M | 125.47M | 48.53M | 42.33M | 36.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 102.85M | 125.47M | 48.53M | 42.33M | 36.01M |
| Cost of Revenue | 76.74M | 125.14M | 174.59M | 213.03M | 274.93M |
| Gross Profit | 26.11M | 330.00K | -126.06M | -170.70M | -238.92M |
| SG&A Expenses | 56.28M | 64.89M | 52.00M | 60.02M | 68.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.02M | 190.03M | 226.59M | 273.04M | 343.85M |
| Operating Income | -30.17M | -64.56M | -178.06M | -230.71M | -307.84M |
| Income Before Tax | -58.31M | -90.58M | -177.06M | -223.52M | -295.63M |
| Income Tax Expenses | -246.00K | -241.00K | -418.00K | -346.00K | -319.00K |
| Earnings from Continuing Operations | -58.06 | -90.34 | -176.64 | -223.18 | -295.31 |
| Earnings from Discontinued Operations | 48.05M | 42.76M | 16.11M | 16.11M | 16.11M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.01M | -47.58M | -121.79M | -168.32M | -240.46M |
| EBIT | -30.17M | -64.56M | -178.06M | -230.71M | -307.84M |
| EBITDA | -27.97M | -61.87M | -173.85M | -224.86M | -300.06M |
| EPS Basic | -2.53 | -12.00 | -30.66 | -42.60 | -61.14 |
| Normalized Basic EPS | -6.02 | -11.19 | -29.08 | -37.41 | -48.99 |
| EPS Diluted | -2.53 | -12.00 | -30.66 | -42.60 | -61.14 |
| Normalized Diluted EPS | -6.02 | -11.19 | -29.08 | -37.41 | -48.99 |
| Average Basic Shares Outstanding | 16.09M | 16.01M | 15.87M | 15.77M | 15.69M |
| Average Diluted Shares Outstanding | 16.09M | 16.01M | 15.87M | 15.77M | 15.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |